Osimertinib Active Not Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02442349Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
NCT02094261Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
NCT03424759Uncommon EGFR AZD9291